{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-029517","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2026-06-22T13:05:10+00:00","discovered_at":"2026-06-22T13:06:00.258928+00:00","generated_at":"2026-06-22T13:06:13.468914+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INVO Fertility Q1 revenue up 23% to $2.0M; net loss widens on warrant charge, balance sheet strengthened","bullets":["Revenue $2.02M (+23% YoY); clinic revenue $1.98M (+22%) driven by organic growth and Family Beginnings acquisition.","Net loss from continuing ops $5.5M (incl. $3.8M non-cash warrant remeasurement) vs $1.5M prior year.","Adjusted EBITDA -$1.26M vs -$0.6M; investments in personnel and infrastructure for future clinic expansion.","Eliminated all Series C-2 Preferred ($2.4M) and warrant liabilities ($1.9M); cash rose to $4.9M from $2.1M at Dec 2025.","Stockholders' equity more than doubled to $15.0M (108% increase); total liabilities down 26% to $9.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-029517","json":"https://secwatch.observer/filing/0001493152-26-029517.json","markdown":"https://secwatch.observer/filing/0001493152-26-029517.md","text":"https://secwatch.observer/filing/0001493152-26-029517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226029517/0001493152-26-029517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226029517/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:06:13.468914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93fd404e013df61841d135c4b09ec74b8a6cd0e6","claim":"INVO Fertility, Inc. reported first quarter ended March 31, 2026 results: revenue $2,015,225, net income $(5.5) million.","evidence_excerpt":"announced financial results for the first quarter ended March 31, 2026. Q1 2026 Financial Highlights (all metrics compared to Q1 2025 unless otherwise noted) ● Revenue was $2,015,225, an increase of 23% compared to $1,637,185. ● Consolidated clinic revenue increased 22% to $1,982,233, compared to $1,621,553. ● Net loss from continuing operations was $(5.5)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226029517/0001493152-26-029517-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$2,015,225"},{"label":"Net income","value":"$(5.5) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}